Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetaphil is a well-known brand of skincare products owned by Galderma. In the context of plaque psoriasis, a specific regimen involving Cetaphil Gentle Skin Cleanser, Cetaphil Moisturizing Cream, and Cetaphil Daily Facial Moisturizer SPF 35 has been investigated as an adjunctive therapy to standard prescription treatments. This regimen is intended for patients with mild-to-severe plaque psoriasis to help manage symptoms such as dryness and scaling. The products work by restoring the skin's natural moisture barrier and providing hydration, which can improve the overall tolerability and efficacy of primary pharmacological treatments. A Phase 4 open-label study (NCT05314101) evaluated this regimen's efficacy and tolerability over an 8-week period, demonstrating improvements in skin hydration and desquamation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetaphil skincare regimen.